OSE Immunotherapeutics Reaffirms Commitment to Holding a Transparent and Serene General Meeting in Compliance with Market Rules

Core Viewpoint - OSE Immunotherapeutics is committed to transparency and compliance with market rules in its upcoming General Meeting, addressing shareholder concerns and misinformation [1][3][5]. Company Actions - The company published a "Questions and Answers" document to clarify recent events and counter false information circulating in the market [2][3]. - A postponement of the General Meeting, originally scheduled for June 25, 2025, was requested and granted to ensure a calm and democratic consultation process [3][5][7]. - OSE has initiated legal proceedings against a group of shareholders challenging the postponement, focusing on the regularity of their concerted action declaration [6][8]. Shareholder Engagement - The company emphasizes the importance of a constructive dialogue with shareholders, proposing a formal framework for discussions to address concerns and move forward collaboratively [8]. Future Plans - Subject to the outcome of legal proceedings, the General Meeting is now planned for September 30, 2025 [7]. Company Overview - OSE Immunotherapeutics is a biotech firm focused on developing innovative treatments in immuno-oncology and immuno-inflammation, partnering with academic and biopharmaceutical entities [9].